|3 Months Ended|
Mar. 31, 2020
|Subsequent Events [Abstract]|
|Subsequent Events||Subsequent Events
Achievement of milestone under Platform Technology Transfer and License Agreement
In April 2020, we achieved a technology transfer milestone associated with the Novartis CodeEvolver® Agreement. We are entitled to receive $4.0 million within 60 days of achievement of the technology transfer milestone.
No definition available.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef